ARTL - artelobio.com Company Long-Term Liabilities

Brandmark of artelobio.com (ARTL)

Current price action on GURU.Markets shows metrics for Artelo Biosciences (ARTL), where long-term debt is fixed at 0.00. The business focuses on the joint study of endocannabinoid mechanisms with clinics to assist cancer patients. Artelo Biosciences (ARTL) develops specific drugs via lipid modulation protected by FDA regulations. Meanwhile, reliable logistics routes in Europe ensure the uninterrupted delivery of licensed raw materials for drug synthesis.

Artelo Biosciences (ARTL) Company Long-Term Liabilities: for the period 07/04/2022 - 10/30/2026

Artelo Biosciences, Inc. (ARTL) - metric breakdowns and financial figures

- stock quotes and analyst forecast:
Price Performance Chart Artelo Biosciences Inc.|ARTL - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Artelo Biosciences|ARTL - Total Company Value
- shareholders' equity book value data:
Net Asset Value per Share Artelo Biosciences|ARTL - Company Net Assets|Market Value to Book Value artelobio.com|ARTL - Company Total Assets
- debt level and financial liquidity data:
Aggregate Debt to Equity Artelo Biosciences|ARTL - Long-Term Debt to Capital|Short-Term Debt to Capital Artelo Biosciences Inc.|ARTL - Company Debts|Debt to Net Assets Ratio Artelo Biosciences|ARTL - Company Long-Term Debt|Company Current Liabilities Artelo Biosciences|Quick Ratio artelobio.com
- earnings and market multiples details:
ARTL - Company Net Income
Analysis of all company metrics:Artelo Biosciences
Finished products of Artelo Biosciences, Inc.

Investors must mitigate financial risks by assessing the issuer's long-term solvency. The operational stability of Artelo Biosciences (ARTL) depends on the success of trials for cannabinoid receptor modulators in treating pain and anorexia. Analyzing the firm's long-term debt reveals confirmed obligations that allow for the identification of abnormal growth in the credit load. A decrease in this metric confirms debt repayment; however, excessive conservatism may slow technological development. The balance of borrowings determines the reliability of the business model.

Competitors of Artelo Biosciences (ARTL)

Company Long-Term Loans and Borrowings INDV|Collegium Pharmaceutical, Inc. - Company Long-Term Debts|Cronos Group Inc (CRON) - Company Long-Term Liabilities|Tweed (CGC) - Company Long-Term Debt|Long-Term Debt Canna Cabana (HITI)|Company Long-Term Liabilities ACB|ACHV: Company Long-Term Loans and Borrowings|Company Long-Term Debts SKYE|ANEB: Long-Term Liabilities|Company Long-Term Debts INCR (InterCure)|Company Long-Term Debts Nutriband Inc NTRB|NSRX - Company Long-Term Debt|Company Long-Term Loans and Borrowings IGC (IGC Pharma, Inc.)|mirapharmaceuticals.com (MIRA) - Company Long-Term Debt|Company Long-Term Liabilities Flora Growth Corp|IMCC (IM Cannabis Corp) - Company Long-Term Debts|Company Long-Term Debts Adial|Company Long-Term Debt Ensysce Biosciences (ENSC)|TTNP (titanpharm.com) - Company Long-Term Loans and Borrowings|Greenlane - Company Long-Term Liabilities|Amount of Long-Term Liabilities INM (InMed Pharmaceuticals Inc)|Akanda Corporation - Company Long-Term Debts|Long-Term Debt Enveric Corp|brightgreen.us (BGXX) - Company Long-Term Debt|HPCO (hempaccoinc.com) - Company Long-Term Debt